Alexander Solms

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Drug Administration

Top Venues

Clinical and translational science

Clinical pharmacology and therapeutics

Clinical pharmacokinetics

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and translational science 17 (4) (2024)
Stefan Willmann, Adam Lloyd, Rupert Austin, Shiju Joseph, Alexander Solms, Yang Zhang, Annika R P Schneider, Sebastian Frechen, Marcus-Hillert Schultze-Mosgau
Population pharmacokinetic-pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data. CPT: pharmacometrics & systems pharmacology (2024)
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and translational science 17 (4) (2024)
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and translational science 17 (4) (2024)
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers. Clinical and translational science 17 (4) (2024)
Hauke Ruehs, Alexander Solms, Matthias Frei, Corina Becker, Maria E Trujillo, Dirk Garmann, Michaela Meyer
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches. Clinical pharmacokinetics (2023)
Jan Hilpert, Esther Groettrup-Wolfers, Hristiyan Kosturski, Laura Bennett, Catriona L K Barnes, Kerstin Gude, Isabella Gashaw, Stefanie Reif, Thomas Steger-Hartmann, Christian Scheerans, Alexander Solms, Antje Rottmann, Guangping Mao, Charles Chapron
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis. Drugs in R&D (2023)
Kosalaram Goteti, Nathan Hanan, Mindy Magee, Jessica Wojciechowski, Sven Mensing, Bojan Lalovic, Yaming Hang, Alexander Solms, Indrajeet Singh, Rajendra Singh, Theodore Robert Rieger, Jin Y Jin
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective. Clinical pharmacology and therapeutics (2023)
Kosalaram Goteti, Nathan Hanan, Mindy Magee, Jessica Wojciechowski, Sven Mensing, Bojan Lalovic, Yaming Hang, Alexander Solms, Indrajeet Singh, Rajendra Singh, Theodore Robert Rieger, Jin Y Jin
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective. Clinical pharmacology and therapeutics (2023)
Alexander Solms, Alfonso Iorio, Maurice J Ahsman, Peter Vis, Anita Shah, Erik Berntorp, Dirk Garmann
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical pharmacokinetics 59 (5) (2021)
Alexander Solms, Shadan Lalezari, Anita Shah, Gili Kenet
Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection. Haemophilia : the official journal of the World Federation of Hemophilia 26 (3) (2020)
Alexander Solms, Anita Shah, Erik Berntorp, Andreas Tiede, Alfonso Iorio, Camila Linardi, Maurice Ahsman, Maria Elisa Mancuso, Tihomir Zhivkov, Toshko Lissitchkov
Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of hematology 99 (11) (2020)